Modernizing clinical trial eligibility criteria: Recommendations of the American society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group

Journal of Clinical Oncology

Volumn 35, Issue 33, 2017, Pages 3753-3759

  Lichtman, Stuart M ^a   Harvey, R Donald ^b   Damiette Smit, Marie Anne ^c   Rahman, Atiqur ^c   Thompson, Michael A ^d   Roach, Nancy ^e   Schenkel, Caroline ^f   Bruinooge, Suanna S ^f   Cortazar, Patricia ^g   Walker, Dana ⁱ   Fehrenbacher, Louis ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d AURORA HEALTH CARE   (United States)

^e Fight Colorectal Cancer (Fight CRC)   (United States)

^f AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^g GENENTECH INC   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESEARCH; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MEDICAL SOCIETY; MODERATE HEPATIC IMPAIRMENT; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; PATIENT SAFETY; PRIORITY JOURNAL; MEDICAL RESEARCH; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PROCEDURES; UNITED STATES;

BIOMEDICAL RESEARCH; COMORBIDITY; ELIGIBILITY DETERMINATION; HUMANS; MEDICAL ONCOLOGY; UNITED STATES;

EID: 85034456630     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.4102     Document Type: Article

References (33)

1. Lara PN Jr, Paterniti DA, Chiechi C, et al: Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23:9282-9289, 2005
2. Bennette CS, Ramsey SD, McDermott CL, et al: Predicting low accrual in the National Cancer Institute's cooperative group clinical trials. J Natl Cancer Inst 108:djv324, 2015
3. Bluethmann SM, Mariotto AB, Rowland JH: Anticipating the "silver tsunami": Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029-1036, 2016
4. Launay-Vacher V, Oudard S, Janus N, et al: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376-1384, 2007
5. Kim ES, Bernstein D, Hilsenbeck SG, et al: Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol 33:2815-2820, 2015
6. Coresh J, Stevens LA: Kidney function estimating equations: Where do we stand?. Curr Opin Nephrol Hypertens 15:276-284, 2006
7. Stevens LA, Li S, Kurella Tamura M, et al: Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: Risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 57:S9-S16, 2011 (suppl 2)
8. Hurria A, Levit LA, Dale W, et al: Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol 33:3826-3833, 2015
9. Rowe JW, AndresR, Tobin JD, et al: The effect of age on creatinine clearance inmen: A cross-sectional and longitudinal study. J Gerontol 31:155-163, 1976
10. Lichtman SM, Cirrincione CT, Hurria A, et al: Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol 34:699-705, 2016
11. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009
12. O'Cearbhaill RE, Miller A, Muggia F, et al: Carboplatin dosing in the treatment of epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 30, 2012 (suppl; abstr 5041)
13. Beumer JH, Ding F, Tawbi H, et al: Effect of renal dysfunction on toxicity in three decades of Cancer Therapy Evaluation Program-sponsored single-agent phase I studies. J Clin Oncol 34: 110-116, 2016
14. O'Bryant CL, Haluska P, Rosen L, et al: An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 69: 605-612, 2012
15. SlingerlandM, Hess D, Clive S, et al: A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol 74:1089-1098, 2014
16. Bello CL, Garrett M, Sherman L, et al: Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 66:699-707, 2010
17. Ramanathan RK, Egorin MJ, Takimoto CH, et al: Phase I and pharmacokinetic study of imatinib mesylate in patientswith advancedmalignancies and varying degrees of liver dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-569, 2008
18. Ramalingam SS, Kummar S, Sarantopoulos J, et al: Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28:4507-4512, 2010
19. Shibata SI, Chung V, Synold TW, et al: Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631-3639, 2013
20. Harvey RD, Morgan ET: Cancer, inflammation, and therapy: Effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther 96:449-457, 2014
21. Albarmawi A, Czock D, Gauss A, et al: CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 77:160-169, 2014
22. Moslehi JJ: Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375: 1457-1467, 2016
23. Townsley CA, Selby R, Siu LL: Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23: 3112-3124, 2005
24. Bellenger NG, Burgess MI, Ray SG, et al: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 21:1387-1396, 2000
25. Curigliano G, Spitaleri G, Fingert HJ, et al: Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44:494-500, 2008
26. Naing A, Veasey-Rodrigues H, Hong DS, et al: Electrocardiograms (ECGs) in phase I anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23:2960-2963, 2012
27. VanderWalde AM, Hurria A: Second malignancies among elderly survivors of cancer. Oncologist 16:1572-1581, 2011
28. Statler A, Radivoyevitch T, Siebenaller C, et al: The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia 31:1808-1815, 2017
29. ClinicalTrials.gov: Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. https://clinicaltrials.gov/ct2/ show/NCT02048813
30. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, et al: Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123:609-616, 2017
31. Criteria Committee of the New York Heart Association: Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis. Boston, MA, Little, Brown and Co, 1964
32. Witteles RM, Telli M: Underestimating cardiac toxicity in cancer trials: Lessons learned?. J Clin Oncol 30:1916-1918, 2012
33. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329, 2004